MYO6 Antibody - #DF9654

Fig. 5. Circ_0011385 regulated MYO6 expression via binding to miR-330-3p. (A) The schema presented the putative binding sites between miR-330-3p and MYO6, and the mutated sites of MYO6. (B–E) Dual-luciferase reporter assay and RIP assay were conducted to demonstrate miR-330-3p was associated with MYO6 in HCT116 and SW480 cells. (F and G) The effects of miR-330-3p mimic on the mRNA and protein expression of MYO6 were determined by qRT-PCR and Western blot, respectively, in HCT116 and SW480 cells. (H) QRT-PCR was utilized to detect the mRNA expression of MYO6 in 50 pairs of CRC tissues and paracancerous normal tissues. (I) TCGA dataset was employed to predict the mRNA expression of MYO6 in CRC tissues (N = 275) and normal tissues (N = 349). (J and K) Western blot was performed to detect the protein expression of MYO6 in 50 pairs of CRC and paracancerous normal tissues and NCM460, HCT116 and SW480 cells. (L and O) Spearman correlation analysis was conducted to determine the linear relationships between MYO6 mRNA expression and miR-330-3p expression or circ_0011385 expression in CRC tissues. (M and N) The impacts between circ_0011385 silencing and miR-330-3p inhibitor on the mRNA and protein levels of MYO6 were revealed by qRT-PCR and Western blot analysis, respectively, in HCT116 and SW480 cells.

Figure 3 Immunohistochemistry of MYO6 expression in adjacent normal and ccRCC carcinoma tissues. The expression of MYO6 protein in adjacent normal tissues was significantly higher than that in cancer tissues. (method: MYO6 was combined with antibody, diaminobenzidine showed the color; Brownish-yellow color is an obvious characteristic.) MYO6, myosin 6; ccRCC, clear cell renal cell carcinoma.